Skip to main content

Table 1 Demographic and baseline characteristics of patients with different severities and virus shedding of COVID-19 infection

From: Discriminant models for the prediction of postponed viral shedding time and disease progression in COVID-19

 

Total

(N = 125)

Non-severe

(N = 97)

Severe/critical

(N = 28)

p

Virus shedding < 14 days (N = 56)

Virus shedding ≥ 14 days (N = 69)

p

 

Median (range)

   

Median (range)

  

Age

44 (34–57)

41 (34–55)

50 (38–63)

0.001

41 (29–54)

45 (37–59)

0.07

Gender

No. (%)

p

No. (%)

p

Male

69 (55.4%)

51 (52.6%)

18 (64.3%)

0.49

34 (59.6%)

35 (50.7%)

0.50

Female

56 (44.6%)

46 (47.4%)

10 (35.7%)

 

22 (40.4%)

34 (49.3%)

 

Epidemic features

No. (%)

p

No. (%)

p

Long-term exposure to Wuhan

38 (30.4%)

33 (34.0%)

5 (17.9%)

0.16

16 (29.8%)

22 (31.9%)

0.84

Short-term exposure to Wuhan

37 (29.6%)

22 (22.7%)

15(53.6%)

0.04

19 (33.3%)

18 (26.1%)

0.45

Local transmitted cases

50 (40%)

42 (43.3%)

8 (28.6%)

0.65

21 (36.8%)

29 (42.0%)

0.64

Comorbidity-No. (%)

61 (37.6%)

31 (32.0%)

28 (100%)

0.000

22 (38.6%)

39 (56.5%)

0.05

Chronic airway disease

5 (4.1%)

3 (3.1%)

2 (7.1%)

0.18

2(3.5%)

3 (4.3%)

0.12

Hypertension

22 (12.0%)

15 (15.5%)

7 (25%)

0.14

8 (15.8%)

14 (20.3%)

0.40

Diabetes mellitus

9 (4.0%)

6 (6.2%)

3 (10.7%)

0.88

2 (3.5%)

7 (10.1%)

0.07

Surgery history

12 (10.4%)

7 (7.2%)

5 (17.9%)

0.15

5 (8.8%)

7 (10.1%)

0.80

Others (ex. kidney stone)

13 (2.4%)

8 (8.2%)

5 (17.9%)

0.24

5 (8.8%)

8 (11.6%)

0.62

Interval from symptom onset to diagnosis (days)

4 (2–7)

4 (2–7)

3 (1.7–7.9)

0.01

5 (1–9)

3 (2–6)

0.07

COVID-19 viral RNA shedding time (days)

14 (11–19.3)

14 (11–18)

16 (13–22)

0.15

10 (8–12)

19 (15–25)

 < 0.001

Interval between outbreak in Liaoning and diagnosis (days)

11 (7–16)

13 (7.5–17.5)

10 (5.5–14.0)

0.01

12 (7–18)

10 (7–16)

0.28

Symptoms

No. (%)

p

No. (%)

p

Fever

103 (82.4%)

75 (77.3%)

28 (100%)

0.006

44 (77.2%)

59 (85.5%)

0.61

Cough

78 (62.4%)

54 (55.7%)

24 (85.7%)

0.004

38 (66.7%)

40 (58.0%)

0.54

Dyspnea/chest tightness

31 (%)

5 (5.2%)

26 (92.9%)

 < 0.001

19 (33.3%)

22 (31.9%)

0.87

Diarrhea/nausea

15 (12%)

12 (12.3%)

3 (10.7%)

0.36

7 (12.3%)

8 (11.6%)

0.91

Fatigue

35 (28%)

22 (22.7%)

13 (46.4%)

0.014

18 (31.6%)

17 (24.6%)

0.46

Signs

No. (%)

p

No. (%)

p

Breath rate > 24/min

10 (8%)

0

10 (35.7%)

0.00

4 (7.0%)

6 (8.7%)

0.83

Laboratory characteristics

Median (range)

p

Median (range)

p

White blood cell, × 109/L

5.16 (3.91–6.30)

5.1 (3.0–6.1)

5.5 (4.6–6.9)

0.20

5.0 (3.6–6.4)

5.2 (4.4–6.2)

0.87

Neutrophil count, × 109/L

3.20 (2.25–4.00)

3.1 (2.1–3.7)

3.8 (2.7.7)

0.002

3.1 (2.0–3.8)

3.3 (2.6–4.0)

0.98

Lymphocyte count, × 109/L

1.20 (0.80–1.70)

1.42 (1.0–1.8)

0.8 (0.5–1.1)

 < 0.001

1.2 (0.8–6.4)

1.2 (0.7–1.6)

0.39

Neutrophil–lymphocyte ratio

2.36 (1.70–4.17)

2.1 (1.6–2.9)

4.9 (2.1–7.8)

 < 0.001

2.1 (1.7–4.0)

2.5 (1.8–4.2)

0.99

C-Reactive Protein, mg/dL

5.40 (1.30–24.0)

3.6 (1.0–9.7)

25 (5.4–66)

 < 0.001

4.6 (1.0–21.9)

5.4 (2.0–25.0)

0.44

Procalcitonin, ng/mL

0.05 (0.00–0.08)

0.04 (0.00–0.05)

0.06 (0.03–0.11)

 < 0.001

0.05 (0–0.05)

0.05 (0–0.09)

0.75

Lactic dehydrogenase, U/L

320.50 (200–456)

267 (177.5–412.0)

400 (321–590)

 < 0.001

312 (200–428)

348 (200–460)

0.56

Creatine kinase, U/L

63.5 (40.0–107.8)

56.0 (38.0–89.5)

109.5 (76–125.9)

 < 0.001

52 (39.5–120)

93.5 (54–213)

0.09

ALT, U/L

29.0 (18.0–45.8)

27.0 (17.0–40.5)

42.0 (24.2–59.3)

0.02

32 (21–45)

27.2 (17.0–46.0)

0.62

AST, U/L

25.9 (20.0–35.0)

24.0 (20.0–30.5)

29.1 (24.4–55.5)

0.03

26 (20–35)

24 (20–39)

0.37

Urea nitrogen, mmol/L

3.7 (3–4.9)

3.6 (3.0–4.7)

4 (2.8–5.3)

0.85

3.5 (3.0–4.4)

4 (3–5)

0.15

Creatinine, mmol/L

57.0 (48.0–66.8)

56.0 (45.5–66.0)

59.5 (49.7–80.5)

0.60

60 (48–67)

55 (47–66)

0.21

0xygenation index, mmHg

371.4 (324.1–377.9)

371.4 (371.0–381.0)

274.6 (225.0–362)

 < 0.001

371.4 (342.9–371.4)

371.4 (323.8–381.0)

0.88

Imaging characteristics

No. (%)

p

No. (%)

p

Normal

17 (13.6%)

17 (17.5%)

0

0.01

7 (12.3%)

4 (5.8%)

0.2

Unilateral GGO

24 (19.2%)

23 (23.7%)

1 (3.6%)

 < 0.001

13 (22.8%)

12 (2.9%)

0.45

Bilateral GGO

87 (69.6%)

62 (63.9%)

25 (89.3%)

 < 0.001

36 (63.2%)

50 (72.5%)

0.27

Diffuse lesions in both lungs

3 (2.4%)

0

3 (10.7%)

0.02

1 (1.8%)

3 (4.3%)

0.15

  1. Data are median (IQR) or No (%). GGO, ground glass opacities
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us